Navigation Links
AACR news: New target plus new drug equals death of melanoma cells
Date:4/9/2013

Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research (AACR) Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them.

"It's exciting in that Mer receptor expression correlates so perfectly with disease progression. It's tiered you see a bump in expression as you transition from nevus to melanoma and then again as you transition from melanoma to metastatic disease," says Doug Graham, MD, PhD, investigator at the CU Cancer Center and associate professor of Pediatrics and Immunology at the University of Colorado School of Medicine, the paper's senior author.

After proving this correlation between Mer receptor expression and disease stage in melanoma tissues from clinical patient samples, Graham and colleagues wondered what would happen if they interrupted this Mer signaling. Luckily, the University of North Carolina had recently developed a new compound that did just that UNC1062. The results were dramatic.

"We showed decreased survival signaling, increased apoptosis and decreased growth of the melanoma cells in dishes and in mouse models," Graham says. It seems that Mer receptors are not only correlated with melanoma progression but are in fact driving the aggressiveness of the disease.

"This is the first time there's been an association between Mer and melanoma and the first time to report about this new drug," Graham says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Page: 1

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
8. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Researchers identify Achilles heel of dengue virus, target for future vaccines
11. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... suggests that fish consumption advisories for expecting mothers ... contaminants like persistent organic pollutants (POPs). , ... including University of Toronto Scarborough PhD student Matt ... different levels of environmental contamination, a mother,s compliance ... the body influenced exposure in her children. , ...
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2
... statistical pattern recognition and image processing to help ... , Under a grant funded by the ... Science Foundation, UC San Diego structural engineering professor ... imagery-based surveillance technique which uses visible and infrared ...
... medical experts in the burgeoning field of interventional ... gather in Las Vegas July 20-23 for the ... from Rush University Medical Center in Chicago will ... course of symposium. On Monday, July 21st, ...
... success when they can thrive without killing their host. ... California Institute of Technology have uncovered how one such ... from the immune system. The human immune system ... a continual dance for survival--viruses ever seek new ways ...
Cached Biology News:UC San Diego researchers could help US military thwart explosive threats 2UC San Diego researchers could help US military thwart explosive threats 3Latest advances in interventional cardiology for congenital heart disease presented 2A viral cloaking device 2A viral cloaking device 3
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... financial results will be released on,Thursday, July 31, 2008. ... at 10:00 a.m. Eastern Time, July 31, 2008, to ... hosted by Steven G.,Anderson, president and CEO of CryoLife, ...
... a disease that strikes an average of 4000 Belgians ... not yet clear. But now, VIB researchers connected to ... cleavage of the Nrg-1 protein lies at the basis ... this molecular process is a first step toward improved ...
... Makes it Easy to Connect with Technology ... on Specific Chemical Reactions, PRINCETON, N.J., July ... portal for manufacturers that require service,and support in ... bio-technology products, industrial products and,higher-value chemicals. The all-new ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2Incorrectly cleaved protein leads to schizophrenia 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 3
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: